News Focus
News Focus
icon url

jessellivermore

04/23/08 8:45 PM

#10266 RE: DewDiligence #10257

Prodarsan............

As a former physician member of the American Academy of Anti-Aging Medicine (A4M) I will not be rushing over to my broker to buy Pharming. Aging is a complex process involving (1)DNA (particularly in the mesenchymal tissues, ie fat, muscle, blood vessels, bone...the suporting structures.) (2) Endrocrine hormone systems particularly sex hormones which may be controlled by a poorly understood mechanism frequently referred to as a biological clock. (3) external physical injury such as radiation which produces free radicals which injure DNA, RNA and cell membranes. Plus emotional,toxilogical and hereitary factors. We think normal is 98.6F, but acually basal tempertures vary from person to person and small differences over time probably play a big role in the rate people age.

IMHO the most interesting aspect of aging involves the terminal portions of the mesenchymal DNA, these ends are called telemeres. During the course of normal cell division these telemers become shorter. After a predetermined number of divisions the telemeres reach a critical length and further cell division is not possible. This results in progressive loss of these cells during aging. Geron has long studied telemeres and their control as cancer cells contain telemerases that rebuild the DNA ends and confer an "immortality".

Reading between the lines and taking into account the progeric disease type the company selected it sounds like Prodarsan must be some free radical trap (it cuts down on DNA injury),,think Vitamin C....The fact it is a small molecule and can be given PO would be consistant with that....This is a field full of smooth operators...
icon url

gym gravity

04/24/08 5:11 AM

#10274 RE: DewDiligence #10257

I really can't remember why I started paying attention to DNAGE a few days ago. maybe it was the symbol change, maybe it was the chart. There must be a bottom somewhere. I hadn't done any homework yet, so I didn't know it was a Pharming company. Anyway, I am watching it and will start picking up shares by the hundredthousands!!! ( closed at $0.0007 today )

http://stockcharts.com/h-sc/ui?s=dnage&p=D&yr=2&mn=0&dy=0&id=p63069675952
icon url

DewDiligence

07/14/08 3:17 PM

#12948 RE: DewDiligence #10257

Pharming to Participate in Study on Biomarkers of Ageing

http://biz.yahoo.com/iw/080714/0415520.html

›Monday July 14, 11:53 am ET

LEIDEN, NETHERLANDS--(MARKET WIRE)--Jul 14, 2008 -- Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today that its wholly owned subsidiary DNage is participating in a large European study, called MARK-AGE, to identify and establish biomarkers of human ageing. Under the Seventh Research Framework Programme (FP7), the European Union has allocated a total budget of almost EUR 12 million for this study for a period of five years.

PharThe consortium is headed by the University of Konstanz (Germany) and brings together 26 research groups from 14 European countries including universities, research centres and companies such as Nestlé Research Center and Unilever. The study includes about 4000 volunteers from different European regions, both men and women between 35 and 74 years old, making it one of the largest studies on biomarkers of ageing of its kind. This large-scale integrating project aims at identifying biomarkers of ageing, i.e. changes in body function or composition which are related to ageing. The resulting biomarkers could predict the onset of age-related diseases and may be used as diagnostic markers or as therapeutic targets. Additional information is available on www.mark-age.eu.

DNage will use its proprietary, accelerated ageing animal models to discover novel biomarkers of ageing, and will recruit patients that suffer from premature ageing (in particular Cockayne Syndrome) to validate the identified biomarkers. The company has programs in the field of premature ageing syndromes, osteoporosis, neurodegeneration and metabolic diseases.

Last May, DNage started a Phase I trial with Prodarsan® to evaluate the pharmacokinetics and tolerability of this product in healthy volunteers. Prodarsan® is a defined combination of small molecules which is being developed to delay premature ageing.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, aging diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for Hereditary Angioedema and human lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via DNage BV). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl.‹